Novartis Malaria Drug May Yield First New Treatment in 30 Years

An experimental Novartis AG medicine that killed drug-resistant malaria in laboratory studies may become the first new class of treatment against the disease in 30 years, researchers said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.